Therapeutic advances for diffuse large B-cell lymphoma in elderly patients
10.12354/j.issn.1000-8179.2023.20230921
- VernacularTitle:老年弥漫性大B细胞淋巴瘤的治疗进展
- Author:
Wanxuan WENG
1
;
Lu GAO
;
Mingqiang REN
Author Information
1. 遵义医科大学附属医院血液内科 贵州省遵义市 563000
- Keywords:
elderly patients;
diffuse large B-cell lymphoma(DLBCL);
therapy;
novel drugs
- From:
Chinese Journal of Clinical Oncology
2023;50(21):1119-1123
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B-cell lymphoma(DLBCL)is more common in the elderly,who often exhibit a poor treatment response,more ad-verse reactions to chemotherapy,and significant inter-individual differences.There is currently no optimal treatment regimen,and the over-all prognosis for elderly patients with DLBCL is poor.The R-CHOP regimen(consisting of rituximab,cyclophosphamide,vincristine,doxorubi-cin,and prednisone)is the standard first-line therapy for DLBCL;however,some elderly patients find it difficult to tolerate.Various treat-ment plans to date have been explored for this specific group,including reducing R-CHOP use,combining R-CHOP with novel drugs,or utiliz-ing new drug combinations.These approaches have achieved varying degrees of success.As the number of treatment options increases,in-dividualized therapy is chosen according to patient age,general physical condition,and comorbidities as well as pathological characteristics of the disease.The key to improving prognosis lies in the early selection of an appropriate treatment plan to enhance remission and reduce recurrence rates.
